Imaging prior to radiotherapy impacts in-vitro survival

Combined biological effects of CBCT and therapeutic X-ray dose on chromosomal aberrations of lymphocytes

BACKGROUND AND PURPOSE

Cone beam computed tomography (CBCT) is routinely used in radiotherapy to localize target volume. The aim of our study was to determine the biological effects of CBCT dose compared to subsequent therapeutic dose by using in vitro chromosome dosimetry.

MATERIALS AND METHODS

Peripheral blood samples from five healthy volunteers were irradiated in two phantoms (water filled in-house made cylindrical, and Pure Image CTDI phantoms) with 6 MV FFF X-ray photons, the dose rate was 800 MU/min and the absorbed doses ranged from 0.5 to 8 Gy. Irradiation was performed with a 6 MV linear accelerator (LINAC) to generate a dose-response calibration curve. In the first part of the investigation, 1-5 CBCT imaging was used, in the second, only 2 Gy doses were delivered with a LINAC, and then, in the third part, a combination of CBCT and 2 Gy irradiation was performed mimicking online adapted radiotherapy treatment. Metaphases were prepared from lymphocyte cultures, using standard cytogenetic techniques, and chromosomal aberrations were evaluated. Estimate doses were calculated from chromosome aberrations using dose-response curves.

RESULTS

Samples exposed to X-ray from CBCT imaging prior to treatment exhibited higher chromosomal aberrations and Estimate dose than the 2 Gy therapeutic (real) dose, and the magnitude of the increase depended on the number of CBCTs: 1-5 CBCT corresponded to 0.04-0.92 Gy, 1 CBCT + 2 Gy to 2.32 Gy, and 5 CBCTs + 2 Gy to 3.5 Gy.

CONCLUSION

The estimated dose based on chromosomal aberrations is 24.8% higher than the physical dose, for the combination of 3 CBCTs and the therapeutic 2 Gy dose, which should be taken into account when calculating the total therapeutic dose that could increase the risk of a second cancer. The clinical implications of the combined radiation effect may require further investigation.

Radiation responses of cancer and normal cells to split dose fractions with uniform and grid fields: increasing the therapeutic ratio

PURPOSE

Radiation treatment of cancer is usually delivered in a prescribed sequence of dose fractions within which the dependence of dose on time is determined by the treatment plan. New techniques, such as stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT) have been introduced with the motivation of improving therapeutic outcomes, with the consequence that the time dependence of the dose within a fraction is modified. Here, we test whether an increased toxicity to cancer cells arises when a radiation treatment fraction is delivered in two equal parts, allowing time for the expression of factors, for example, RONS and cytokines, in response to the first dose which may sensitize cells to the second dose. A medium time delay between 15 and 60 minutes is proposed to allow factors to be expressed before repair takes place. A grid field is used to enhance diffusion of the factors.

MATERIALS AND METHODS

The cell lines used in the study were two prostate cancers (LNCaP and DU 145), a normal prostate (PNT1A), a non-small cell lung cancer (NCI-H460), and a glioma (Hs 683). Uniform or spatially modulated grid fields, delivering the same mean dose, were used. The results for the clonogenic survival fractions were grouped into a 'short' delay (under 10 minutes) and a 'medium' delay (between 15 and 60 minutes).

RESULTS

The medium delay with a grid field yielded a significant increase in toxicity for the four cancer cell lines. The medium delay with a uniform field gave a significant increase in toxicity for the two prostate cancer cell lines. A highly significant increase was found in the therapeutic ratio, defined as the ratio of the survival of prostate normal to prostate cancer cells.

CONCLUSIONS

The findings show that the intra-fractional dose schedule with medium time delay offers an opportunity to increase the toxicity of radiation to cancer cells, relative to a single radiation delivery. For all cancer cell lines, a grid field gives a greater toxic effect than a uniform field. The split dose treatment offers an increase in cancer toxicity while preserving normal cells, improving the outcomes of a treatment.

PCXMC cone beam computed tomography dosimetry investigations

With cone beam computed tomography (CBCT) in image guided radiation therapy being amongst the most widely used imaging modalities, there has been an increasing interest in quantifying the concomitant dose and risk. Whilst there have been several studies on this topic, there remains a lack of standardisation and knowledge on dose variations and the impact of patient size. Recently, PCXMC (a Monte Carlo simulator) has been used to assess both the concomitant dose and dosimetric impact of patient size variations for CBCT. The scopes of these studies, however, have included only a limited range of imaging manufacturers, protocols, and patient sizes. An approach using PCXMC and MATLAB was developed to enable a generalised method for rapidly quantifying and formulating the concomitant dose as a function of patient size across numerous CBCT vendors and protocols. The method was investigated using the Varian on board imaging 1.6 default pelvis and pelvis spotlight protocols, for 94 adult and paediatric phantoms over 6 age groups with extensive height and mass variations. It was found that dose varies significantly with patient size, as much as doubling and halving the average for patients of lower and higher mass, respectively. These variations, however, can be formulated and accounted for using the method developed, across a wide range of patient sizes for all CBCT vendors and protocols. This will enable the development of a comprehensive catalogue to account for concomitant doses in almost any clinically relevant scenario.